Based on the key indicators related to RAPT Therapeutics' liquidity, profitability, solvency, and operating efficiencyBased on the analysis of, RAPT Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in January. At this time, RAPT Therapeutics' Short Term Debt is comparatively stable compared to the past year. Short Term Investments is likely to gain to about 157.8 M in 2024, whereas Total Stockholder Equity is likely to drop slightly above 119 M in 2024. Key indicators impacting RAPT Therapeutics' financial strength include:
The essential information of the day-to-day investment outlook for RAPT Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor RAPT Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in RAPT Therapeutics.
Please note, the imprecision that can be found in RAPT Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of RAPT Therapeutics. Check RAPT Therapeutics' Beneish M Score to see the likelihood of RAPT Therapeutics' management manipulating its earnings.
RAPT Therapeutics Stock Summary
RAPT Therapeutics competes with Candel Therapeutics, Unicycive Therapeutics, Cardio Diagnostics, Senti Biosciences, and Cadrenal Therapeutics,. RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. Rapt Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 88 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what RAPT Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining RAPT Therapeutics's current stock value. Our valuation model uses many indicators to compare RAPT Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across RAPT Therapeutics competition to find correlations between indicators driving RAPT Therapeutics's intrinsic value. More Info.
RAPT Therapeutics is currently regarded as top stock in return on equity category among its peers. It is rated second in return on asset category among its peers . At this time, RAPT Therapeutics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value RAPT Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
RAPT Therapeutics Systematic Risk
RAPT Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. RAPT Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on RAPT Therapeutics correlated with the market. If Beta is less than 0 RAPT Therapeutics generally moves in the opposite direction as compared to the market. If RAPT Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one RAPT Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of RAPT Therapeutics is generally in the same direction as the market. If Beta > 1 RAPT Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in RAPT Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various RAPT Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of RAPT Therapeutics growth as a starting point in their analysis.
RAPT Therapeutics December 4, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of RAPT Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of RAPT Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of RAPT Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing RAPT Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build RAPT Therapeutics's daily price indicators and compare them against related drivers.
When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.